SoGAT XVII, Paris, Paris 2004 - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

SoGAT XVII, Paris, Paris 2004

Description:

B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion Service Baden-W rttemberg Hessen, Institute Frankfurt am Main – PowerPoint PPT presentation

Number of Views:83
Avg rating:3.0/5.0
Slides: 14
Provided by: WKR3
Learn more at: https://www.nibsc.org
Category:
Tags: sogat | xvii | anemia | aplastic | paris

less

Transcript and Presenter's Notes

Title: SoGAT XVII, Paris, Paris 2004


1
SoGAT XVII, Paris, Paris 2004
B19 Overview of Testing for Blood Banks
W. Kurt Roth Red Cross Blood Transfusion Service
Baden-Württemberg Hessen, Institute Frankfurt
am Main
2
Parvovirus B19-PCR Testing Strategy
  • Quantitative real-time TaqMan PCR
  • Internal control sequence
  • 3 external quantitative standards 106, 105, 104
    IU/ml on each plate
  • External standards are spiked in negative plasma
  • Routine donor screening on pools of 96
  • Testing in parallel with HCV, HIV, HBV, HAV
  • Testing for all blood components incl. red cells
    and platelets
  • No exclusive and no delayed testing for source
    plasma
  • 95 detection limit 103 IU / ml
  • Decision level ? 105 IU / ml

3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
Parvo B19 Positives per Month
Positives 105 (n)
7
B19 positives in March - April 2004
sensitivity n donations n positive donations positive donations rate n pools n positive pools positive pools
105 72,972 23 0.03 1 3,173 902 19 2.1
103 72,972 130 0.18 1 561 902 130 14.4
105 68,147 25 0,04 1 2,726 883 23 2.6
103 68,147 139 0,20 1 490 883 139 15.7

March
April
Indicates at least 1 donation/pool
8
Parvovirus B19-PCR Decision Making
  • B19 positive Pools ? 105 IU / ml
  • Positive donation identified
  • Positive donation destroyed
  • No donor deferral
  • No donor information or counseling
  • Reentry after donor tests PCR-negative (detection
    limit lt 100 IU/ml)
  • B19 weak positive Pools lt 105IU / ml
  • Positive donation not identified
  • All donations released (weak positive for blood
    bank software)
  • No labelling of product as B19 weak positive
  • Parvo B19-negative and weak positive (gt 103 lt
    105 IU / ml) components for all patients at no
    specific risk
  • standard quality

9
Indications for B19-negative components
  • Parvo B19-negative (lt 103 IU / ml) components
    upon specific written request individual label
    Parvovirus B19 not detectable
  • Patients with BMT, SCT
  • B19 antibody-negative pregant women in the 1.and
    2. trimenon
  • HIV patients
  • Additional risk groups e.g.
  • transient aplastic crisis
  • pure red cell aplasia

10
The Netherlands approach Cellular components
  • B19 virus safe cellular products to risk groups
    only
  • Pregnant women
  • Patients with congenital or acquired haemolytic
    anemia who have no antibodies
  • Patients with cellular immunodeficiency who have
    no antibodies
  • Safe products are
  • IgG antibodies against B19 in two separate blood
    samples, one taken at least six months after the
    other.
  • To be introduced in 1st of July 2004
  • To be introduced for quarantine plasma in April
    2005

11
The Netherlands Approach Plasma Products
  • All products derived from pooled plasma
  • Highly infectd donations should be identified and
    removed before the individual sampkles are
    pooled.
  • For final pools the maximum permissible limit is
    104 genome copies of B19 per millilitre.
  • NAT for pools of 480 (10 x 48)
  • one central facility ín Amsterdam.
  • minipool NAT for HCV and HIV pools of 48 at 4
    test centers.

12
The future approach?
  • B19 PCR and Ab testing on all donations
  • Release PCR-only negatives and PCR negatives/Ab
    positives
  • PCR negative/Ab positive products for patients at
    risk and source plasma
  • Discontinue PCR and Ab testing for repeat
    PCR-negatives/Ab positives
  • Continue PCR and Ab testing for first-time
    donors, antibody negative and PCR positive
    donors.

13
Parvo-B19 Seroconversion
Medac IgM and IgG ELISA Mikrogen IgG/IgM
recomBlot
Write a Comment
User Comments (0)
About PowerShow.com